Taizo Ono

Taizo Ono

Auto-generated profile, based on publicly available information

Taizo Ono

National Institute of Advanced Industrial Science and Technology (AIST), Anagahora, Shimoshidami, Moriyama-ku, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Ukrainian Chemistry Journal
Verified
Journal Article
Open access
PDF file
JHJianlin Han
Jianlin Han
AWAlicja Wzorek
Alicja Wzorek
GDGagan Dhawan
Gagan Dhawan
Wei ZhangWei Zhang
Wei Zhang
ASAlexander E. Sorochinsky
Alexander E. Sorochinsky
VSVadim A. Soloshonok
Vadim A. Soloshonok
This article profiles five newly drugs containing fluorine along with fragments of amino acids or their derivatives approved by the FDA in 2024. These pharmaceuticals include Voy­deya® (danicopan), Ojemda® (tovorafenib), Itovebi® (inavolisib), Scemblix® (asciminib), and Revuforj® (revumenib). For each drug, we discuss the discovery, therapeutic areas of application, and detailed chemical synthesis.

25 March 2025 in Ukrainian Chemistry Journal
Verified
Journal Article
Open access
PDF file
JHJianlin Han
Jianlin Han
AWAlicja Wzorek
Alicja Wzorek
GDGagan Dhawan
Gagan Dhawan
Wei ZhangWei Zhang
Wei Zhang
ASAlexander E. Sorochinsky
Alexander E. Sorochinsky
VSVadim A. Soloshonok
Vadim A. Soloshonok
Fluorine is a key element in drug design due to its ability to enhance metabolic stability, binding affinity, and bioavailability. Fluorine’s properties lead to more stable drugs with longer half-lives, reducing dosing frequency and improving patient compliance. Its small size and high electronegativity also improve binding affinity, resulting in more effective treatments with lower doses. For example, fluorine increases a compound’s ability to cross cell memb­ranes. This article highlights advancements in chiral, fluorine-containing pharmaceuticals introduced over the past five years, focusing on their synthesis, therapeutic benefits, mechanisms of action, and the impact of fluorine on efficacy and safety. Chiral molecules, essential in drug development, exist in two enantiomeric forms with distinct biological activities. Synthesizing chiral, fluorine-containing drugs involves techniques like asymmetric synthesis to produce pure enantiomers, resulting in drugs with increased potency, selectivity, and reduced side effects. Understanding their mechanisms of action provides valuable insights into efficacy and safety. Reviewing recently FDA-approved chiral drugs offers insights into fluorine chemistry in drug development and future therapeutic innovations. Recent FDA approvals highlight the significance of chiral, fluorine-containing drugs in various therapeutic areas, enabling targeted and effective treatments. Analyzing these approvals reveals trends shaping drug development’s future. The article also addresses the need for more research into self-disproportionation of enantiomers (SDE) in chiral, fluorinated compounds and concerns about excessive fluorine levels. SDE can affect pharmaceutical product purity. Research into SDE in fluorinated compounds ensures drug quality. Additionally, fluorine’s widespread use raises environmental and health concerns, necessitating studies on long-term effects and mitigation strategies.

25 July 2025 in Ukrainian Chemistry Journal
Verified
Journal Article
Open access
PDF file
JHJianlin Han
Jianlin Han
AWAlicja Wzorek
Alicja Wzorek
TOTaizo Ono
Taizo Ono
KKKarel D. Klika
Karel D. Klika
VSVadim A. Soloshonok
Vadim A. Soloshonok
This review profiles ten marketed pharmaceuticals approved by the US Food and Drug Agency within the last five years that feature aliphatic fluorination – a key structural feature pivotal to their biological activity. These include ivosidenib, developed for the treatment of acute myeloid leukemia and cholangiocarcinoma (bile duct cancer); ubrogepant, approved for the acute treatment of migraines; asciminib, prescribed for the treatment of chronic my­eloid leukemia in the chronic phase; omaveloxolone, used in the treatment of Friedreich’s ataxia, a rare genetic disorder causing progressive damage to the spinal cord, peripheral nerves, and brain; flurpiridaz (18F), a radioactive diagnostic agent for myocardial perfusion imaging by positron emission tomography; upadacitinib, designed to address several inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis; tezacaftor, approved for the treatment of cystic fibrosis as an effective remedy; alpelisib, prescribed for the treatment of breast cancer, effectively inhibiting tumor growth and abnormal cell proliferation; pretomanid, used in combination therapies for the treatment of extensively drug-resistant and multi-drug-resistant tuberculosis; and atogepant, approved for the preventive treatment of migraines in adults, targeting both episodic and chronic migraines. Molecules featuring aliphatic fluorination present challenges due to higher production costs and the complexity of predicting their biological profiles. However, the undeniable medicinal benefits of aliphatic fluorination invigorate this area of research, paving the way for the development of more innovative drugs to enter the pharmaceutical market. Beyond the incorporation of aliphatic fluorine atoms, six of the pharmaceuticals discussed in this review feature residues of amino acids or their derivatives as pivotal structural design ele­ments. Another characteristic shared by all these drugs is their chirality, with each molecule possessing between one and six stereogenic carbons. Special attention should be directed toward the phenomenon of self-disproportionation of enantiomers (SDE), a behavior observed in enantiomerically enriched compounds. The SDE properties of chiral drugs, particularly those containing fluorine and/or amino acid residues, represent a vital public safety concern, necessitating rigorous evaluation of enantiomeric purity. Additionally, caution should be exer­cised in light of growing public concerns over the potential harmful effects of fluorine on human health. Since fluoride is recognized as the final metabolite of organic fluorinated compounds, patients prescribed fluorine-containing drugs should consult their physicians about non-fluorinated alternatives where available or take steps to limit fluoride exposure from other sources, such as fluoridated water and industrially produced foods treated with fluorinated agrochemicals. Despite these concerns, it remains an undeniable fact that fluorine-containing drugs are indispensable in modern medicine. They provide life-saving treatments, improve quality of life, and drive medical innovation addressing urgent health challenges and laying the foundation for future advancements in healthcare.

29 November 2024 in Ukrainian Chemistry Journal
Verified
Journal Article
Open access
PDF file
JHJianlin Han
Jianlin Han
HLHong Liu
Hong Liu
JWJiang Wang
Jiang Wang
AWAlicja Wzorek
Alicja Wzorek
ASAlexander E. Sorochinsky
Alexander E. Sorochinsky
VSVadim A. Soloshonok
Vadim A. Soloshonok
This article reviews the development of the asymmetric synthesis of tailor-made amino acids conducted at Hamari Chemicals during the 10-year period 2013–2022.The discussion is based on strategies such as direct chiral modification of unprotected amino acids via intermediate formation of Ni(II) complexes and elaboration of chiral nucleophilic or electrophilic glycine equivalents. The former approach includes, for example, second-order asymmetric transformation, dynamic kinetic resolution, and inversion of chirality while the latter approach involves construction of the desired amino acid architecture using, for example, alkylation, aldol, Mannich, or Michael addition reactions as well as multistep procedures. Operational convenience, scalability, and practicality of the developed methods are emphasized.

25 April 2025 in Ukrainian Chemistry Journal
Verified
Journal Article
Open access
PDF file
AWAlicja Wzorek
Alicja Wzorek
KKKarel D. Klika
Karel D. Klika
JHJianlin Han
Jianlin Han
ASAlexander E. Sorochinsky
Alexander E. Sorochinsky
TOTaizo Ono
Taizo Ono
VSVadim A. Soloshonok
Vadim A. Soloshonok
Enantiomer purification is a critical process in the pharmaceutical, agrochemical, and food industries, where chiral compounds often exhibit distinct biological activities. Traditional chiral chromatography is effective but costly due to the use of expensive chiral stationary phases. This review article highlights a recent breakthrough in enantiomer purification under entirely achiral conditions. Specifically, it focuses on the convergence of achiral simulated moving bed chromatography and the phenomenon of self-disproportionation of enantiomers (SDE). Experimental validation using scalemic methyl p-tolyl sulfoxide as a model compound enabled the isolation of the excess enantiomer with high purity (99% ee) and a respectable yield (~50%). This innovative process features exceptional productivity (up to 99 grams per liter of column volume per day), reproducibility, and reliability. This breakthrough presents the first practical example of enantiomer purification based on SDE, offering a scalable and economically viable alternative to conventional chiral separations. Given that SDE is an inherent property of all chiral compounds, this innovative approach is anticipated to become the method of choice for practical enantiomer purification in both research and industrial production.

30 June 2024 in Ukrainica Bioorganica Acta
Verified
Journal Article
Open access
PDF file
AWAlicja Wzorek
Alicja Wzorek
JHJianlin Han
Jianlin Han
NLNataliya V. Lyutenko
Nataliya V. Lyutenko
MKManankar Koley
Manankar Koley
ASAlexander E. Sorochinsky
Alexander E. Sorochinsky
VSVadim A. Soloshonok
Vadim A. Soloshonok
In this perspective review article, we discuss application of penicillin acylase for biocatalytic resolution of tailor-made amino acids, in particular α-aminophosphonic acids and fluorine-containing β-amino acids. The method includes preparation of the corresponding N-phenylacetyl derivatives followed by the enzyme-catalyzed hydrolysis of one of the enantiomers. The free amino acid and the remaining N-phenylacetyl derivative are separated simply by cation-exchange chromatography or extraction. The final step is a chemical hydrolysis of the enzymatically unreactive N-phenylacetyl derivative. This approach features exceptionally high enantiomeric purity (>99% ee) of the target amino acids, wide structural generality and operational simplicity boding well for large-scale applications of this biocatalytic approach for preparation of highly biologically relevant unnatural, tailor-made amino acids in enantiomerically pure form